Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$2.81 USD
-0.18 (-6.02%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $2.81 0.00 (0.00%) 4:58 PM ET
4-Sell of 5 4
D Value F Growth C Momentum F VGM
Brokerage Reports
Aquestive Therapeutics, Inc. [AQST]
Reports for Purchase
Showing records 81 - 100 ( 399 total )
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Leadership Transition; Libervant Limbo Persists; Lowering PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Q1: AQST-109 Progress; Delay Continues for Potential Libervant Approval
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Part 2 Results from EPIPHAST Study, EPIPHAST Completion in Q2:22
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L